This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Felgar, R. E. Articles by Macon, W. R. Search for Related Content PubMed PubMed Citation Articles by Felgar, R. E. Articles by Macon, W. R.

(American Journal of Pathology. 1998;153:1707-1715.)
© 1998 American Society for Investigative Pathology

Short Communications

T-Cell-Rich Large-B-Cell Lymphomas Contain Non-Activated CD8⁺ Cytolytic T Cells, Show Increased Tumor Cell Apoptosis, and Have Lower Bcl-2 Expression Than Diffuse Large-B-Cell Lymphomas

Raymond E. Felgar* , Katherine R. Steward* , John B. Cousar* and William R. Macon*

From the Department of Pathology,* Division of Hematopathology, Vanderbilt University Medical Center, Nashville, Tennessee, and the Department of Pathology and Laboratory Medicine, Allegheny University of the Health Sciences, MCP-Hahnemann School of Medicine, Philadelphia, Pennsylvania

The factor(s) responsible for the reduced B cell number and increased T cell infiltrate in T-cell-rich large-B-cell lymphomas (TCRBCLs) have not been well characterized. We studied 18 TCRBCLs and 12 diffuse large-B-cell lymphomas (DLBCLs) to compare the 1) predominant T cell subpopulation(s), 2) expression of cytotoxic granule proteins (TIA-1 and granzyme B), 3) level of tumor cell apoptosis (Apoptag system, Oncor, Gaithersburg, MD), and 4) expression of Ki-67 (Mib-1) and apoptosis-related proteins (fas (CD95), bcl-2, and p53). T cells in TCRBCLs and DLBCLs were predominantly CD8⁺ T cells expressing ß T-cell receptors and TIA-1 (16 of 18 TCRBCLs with >50% TIA-1⁺ small lymphocytes) but lacking granzyme B (16 of 18 TCRBCLs with <25% granzyme B⁺ small lymphocytes). Scattered apoptotic tumor cells (confirmed with CD20 co-labeling) were present in 15 of 18 TCRBCLs, with 14 of 15 cases having <10% apoptotic cells. No apoptotic cells were seen in 12 of 12 DLBCLs. In 16 of 16 immunoreactive TCRBCLs, <25% tumor cells were bcl-2⁺, whereas 6 of 12 DLBCLs had >50% bcl-2⁺ tumor cells. CD95 (fas) expression was also lower, with 3 of 18 (16.7%) TCRBCLs versus 4 of 12 (33%) DLBCLs having >25% CD95⁺ tumor cells. TCRBCLs and DLBCLs had similar levels of p53 and Ki-67 (Mib-1) expression. Thus, T cells in TCRBCLs are non-activated cytotoxic T lymphocytes (TIA-1⁺, granzyme B^-). Tumor cell apoptosis (perhaps cytotoxic T cell mediated) may partly account for the decreased number of large (neoplastic) B cells in TCRBCLs, but other factors (ie, decreased bcl-2 expression) may also be needed.

This article has been cited by other articles:

				T Mitterlechner, M Fiegl, H Muhlbock, W Oberaigner, S Dirnhofer, and A Tzankov Epidemiology of non-Hodgkin lymphomas in Tyrol/Austria from 1991 to 2000 J. Clin. Pathol., January 1, 2006; 59(1): 48 - 55. [Abstract] [Full Text] [PDF]

				L. Nogova, T. Rudiger, and A. Engert Biology, Clinical Course and Management of Nodular Lymphocyte-Predominant Hodgkin Lymphoma Hematology, January 1, 2006; 2006(1): 266 - 272. [Abstract] [Full Text] [PDF]

				L. Boudova, E. Torlakovic, J. Delabie, P. Reimer, B. Pfistner, S. Wiedenmann, V. Diehl, H.-K. Muller-Hermelink, and T. Rudiger Nodular lymphocyte-predominant Hodgkin lymphoma with nodules resembling T-cell/histiocyte-rich B-cell lymphoma: differential diagnosis between nodular lymphocyte-predominant Hodgkin lymphoma and T-cell/histiocyte-rich B-cell lymphoma Blood, November 15, 2003; 102(10): 3753 - 3758. [Abstract] [Full Text] [PDF]

				J. P. Greer and W. Macon Am. J. Pathol., July 1, 1999; 155(1): 325 - 326. [Full Text] [PDF]